dc.contributor.author | Leissinger, C. | |
dc.contributor.author | Cortesi, P. A. | |
dc.contributor.author | Jo, H. | |
dc.contributor.author | Antmen, B. | |
dc.contributor.author | Berntorp, E. | |
dc.contributor.author | Biasoli, C. | |
dc.contributor.author | Carpenter, S. | |
dc.contributor.author | Kavakli, K. | |
dc.contributor.author | Morfini, M. | |
dc.contributor.author | Negrier, C. | |
dc.contributor.author | Rocino, A. | |
dc.contributor.author | Schramm, W. | |
dc.contributor.author | Windyga, J. | |
dc.contributor.author | Mantovani, L. G. | |
dc.contributor.author | Zulfikar, B. | |
dc.contributor.author | Gringeri, A. | |
dc.contributor.author | Fusco, F. | |
dc.contributor.author | Riva, S. | |
dc.date.accessioned | 2021-03-06T08:47:13Z | |
dc.date.available | 2021-03-06T08:47:13Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Gringeri A., Leissinger C., Cortesi P. A. , Jo H., Fusco F., Riva S., Antmen B., Berntorp E., Biasoli C., Carpenter S., et al., "Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study", HAEMOPHILIA, cilt.19, ss.736-743, 2013 | |
dc.identifier.issn | 1351-8216 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_e2a398fc-d9f5-4caf-afff-b0a624fa0561 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/149166 | |
dc.identifier.uri | https://doi.org/10.1111/hae.12178 | |
dc.description.abstract | Patients with haemophilia A and inhibitors are at high risk for severe bleeding, progression of joint disease and deterioration of health-related quality of life (HRQoL). To determine the impact of prophylaxis with an activated prothrombin complex concentrate (aPCC) on HRQoL, HRQoL was assessed using the Short-Form (SF)-36 Health Survey and the EQ-5D questionnaire in subjects 14years participating in a prospective, randomized, crossover study comparing 6months of aPCC prophylaxis with 6months of on-demand therapy. Eighteen of 19 patients completed the survey or questionnaire before and after the on-demand therapy and prophylaxis periods. A general trend towards improved HRQoL after prophylaxis was observed for the 18 evaluable patients in all SF-36 dimensions except for vitality/energy and physical functioning. After prophylaxis, good responders,' defined as patients experiencing 50% reduction in bleeding, exhibited statistically and clinically significant differences in the physical component score (P=0.021), role - physical (P=0.042), bodily pain (P=0.015), and social functioning (P=0.036). Similarly, the EQ-5D health profile showed a trend towards improvement after prophylaxis in all evaluable patients. Among the good responders, improvements did not differ from those observed after on-demand treatment. EQ visual analogue scale values were slightly improved following prophylaxis for all evaluable patients and the EQ-5D utility index improved in the good responders only. During prophylaxis, patients missed significantly fewer days from school or work because of bleeding than during on-demand treatment (P=0.01). In conclusion, by significantly reducing bleeding frequency in good responders, aPCC prophylaxis improved HRQoL compared with on-demand treatment. | |
dc.language.iso | eng | |
dc.subject | Hematoloji | |
dc.subject | HEMATOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Hematology | |
dc.subject | Health Sciences | |
dc.title | Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study | |
dc.type | Makale | |
dc.relation.journal | HAEMOPHILIA | |
dc.contributor.department | University of Milan , , | |
dc.identifier.volume | 19 | |
dc.identifier.issue | 5 | |
dc.identifier.startpage | 736 | |
dc.identifier.endpage | 743 | |
dc.contributor.firstauthorID | 210981 | |